

Ralph J. DeBerardinis, MD, PhD,
one of five new Damon Runyon
Clinical Investigators

Accelerating Cancer Cures

In June, six pharmaceutical companies—despite being competitors in the marketplace—launched an historic collaboration with Damon Runyon and academia to rebuild the ranks of elite physician-scientists, those capable of translating lab discoveries into clinical treatments. The collaboration will leverage the highly successful Damon Runyon Clinical Investigator Award.

Accelerating Cancer Cures targets the national shortage of clinical investigators, specially trained physicians who conduct lab research and see patients. While many of the last decade's most important advances against cancer have come from these physician-scientists, a **"perfect storm" has developed in which top young physicians are not choosing careers in clinical research.** The extended length of training, an uphill battle to obtain funding, and staggering medical school debt that averages \$125,000 compels them to choose a career in the clinic over one in the lab.

Over the next five years, Accelerating Cancer Cures aims to invest **\$25 million to fund 50 new scientists** selected as part of our Clinical Investigator Award program, which was launched in 2000. The Award provides each Investigator with \$450,000 over three years for salary, research, and staffing expenses and pays up to \$100,000 for medical school debt. Fifty-eight outstanding Clinical Investigators have received the prestigious award; **today, they are leaders in their fields.** (You can read about their groundbreaking work at www.damonrunyon.org/accelerate, or meet our five newest Investigators on page three.)

In addition to financial support, Accelerating Cancer Cures will provide opportunities for Damon Runyon Clinical Investigators to network and collaborate with industry researchers. Because they recognize Damon Runyon's unique role and expertise, Eli Lilly and Company, Celgene, Merck, Millennium: The Takeda Oncology Company, and Pfizer, along with the Pharmaceutical Research and Manufacturers of America, have already pledged more than \$5.1 million to this project. As Richard Gaynor, MD, Vice President of Product Development and Medical Affairs at Lilly Oncology, noted, "Damon Runyon's prestigious track record of identifying and supporting high-caliber talent makes them the natural leader for this effort."

ACCELERATING CANCER CURES

Learn more at
damonrunyon.org/accelerate

RECENT DISCOVERIES & ACCOLADES

VITAMIN D AND CALCIUM MAY CUT RISK OF MELA- NOMA FOR SOME WOMEN

Damon Runyon Clinical Investigator Jean Y. Tang, MD, PhD, recently found that women with a history of non-melanoma skin cancer who took a vitamin D-calcium combination developed 57 percent fewer melanomas than similar women who did not take the supplements. Jean will research the connection more extensively, adding to a growing collection of studies that suggests a relationship between vitamin D levels and a reduced risk of skin, colon, breast, prostate and other cancers.

BLOCKING OVERACTIVE GENES IN HARD-TO-TREAT BREAST CANCERS

Former Damon Runyon Fellows William C. Hahn, MD, PhD, and Serena J. Silver, PhD, have discovered a set of overactive genes, known as the Jak2/Stat3 pathway, that help drive the growth of triple-negative breast tumors. These notoriously aggressive tumors account for 15 to 20 percent of breast cancers. Researchers say that blocking the pathway in mouse models halted tumor growth, and that Jak2/Stat3 treatments currently being tested for blood cancers may soon be tested for breast cancer patients.



Green spots show Stat3 activation
in a breast cancer tumor.

NEW STRATEGY FOR IDENTIFYING AND SCREENING CANCER BIOMARKERS

Former Damon Runyon Fellow Amanda Paulovich, MD, PhD, and former Scholar Peter S. Nelson, MD, have pioneered a new method for testing biomarkers, an important but complex and expensive process. Amanda and Peter created a more efficient approach that uses sensitive technology to find select biomarkers in the blood, determines whether they are elevated in individuals with cancer, and creates a blood test to detect those biomarkers. Using this approach in mice with breast cancer, they identified a set of relevant biomarkers that were elevated before the tumor could be seen, a promising step forward for early cancer detection.

FALL /
WINTER
2011

INSIDE

02

Runyon 5K at
Yankee Stadium
Raises \$650k



03

Emerging
Leaders in Clinical
Research

04

\$2.8M Invested
in 18 Elite Fellows

05


Alumni Profile:
Linda S.
Birnbaum, PhD

06

Have a Seat,
Help a Scientist

PLUS

Innovative
Research for
Pediatric Cancer



HONORING A BOSTON LEADER

In June, we held our Annual Breakfast in New York City, raising \$1.16 million to support the most brilliant minds in cancer research.

The morning featured a panel discussion with Memorial Sloan-Kettering President Craig Thompson, MD, The Rockefeller University's Elaine Fuchs, PhD, and Ken Cadwell, PhD, one of the first recipients of our Dale F. Frey Award for Breakthrough Scientists.

The Breakfast honored Norman Leventhal for his visionary civic leadership as the founder of The Beacon Companies and one of Boston's leading philanthropists. In his honor, Damon Runyon scientist Daniel Schmidt, PhD, of MIT, was named the Norman B. Leventhal Fellow. An MIT alumnus, Norman has committed more than half a century to supporting higher education and the pursuit of scientific knowledge.



ABOVE: Leventhal family members have been longtime supporters of Damon Runyon. Left to Right: Alan, Sherry, Jeremy, Norman, Muriel, and Alexander.



LEFT: Damon Runyon Board Members David M. Livingston, MD, (left) and Scott Greenstein (right).

RESSAS WIN FIRST-EVER RUNYON 5K MVP PRIZE PACKAGE

Carl Ressa, a cancer survivor and three-time Runyon 5K top fundraiser from Rockville, Maryland, won the first-ever Runyon 5K MVP Prize Package for raising \$10,000 by July 29. He and his wife Jennifer won a private flight to Boston, two premium tickets to a New York Yankees-Boston Red Sox game at Fenway Park on August 7, and a night at the Boston Harbor Hotel. Earlier this summer, they used tickets they won as part of last year's top fundraising prize to attend the July 11 game during which Derek Jeter hit his historic 3,000th hit!

“What an inspiring, challenging, well-organized run with enthusiastic participants and volunteers. I can’t wait until next year!” — *Beth Ann DiBella, Runyon 5K participant*

RUNYON 5K AT YANKEE STADIUM RAISES \$650,000

Four thousand runners, baseball fans, cancer survivors, and supporters of cancer research took part in our third annual Runyon 5K at Yankee Stadium, the only charitable run/walk that uses the legendary ballpark as its course.

Participants from 30 states ran victory laps around the warning track that surrounds the field and saw themselves on the center field video board. Former New York Yankee Roy White kicked off the 5K with special guests Michael Gargiulo of NBC4 and Thomas Werner, Chairman of the Boston Red Sox. Damon Runyon Board Chairman Alan Leventhal noted that Werner attended “because even one of the oldest rivalries in baseball can be set aside to support the fight against cancer.”

Thanks to you, our supporters, we raised \$650,000 for cancer research!



LEFT: (L to R) NBC4's Michael Gargiulo, former Yankee Roy White, Damon Runyon Executive Director Lorraine Egan, Damon Runyon Board Chairman Alan Leventhal, and Boston Red Sox Chairman Tom Werner.

For photos, videos and more, visit www.damonrunyon.org/yankeestadium or www.facebook.com/runyon5k

Emerging Leaders in Clinical Research


On the cover, we told you about Accelerating Cancer Cures, our initiative to fund 50 new Damon Runyon Clinical Investigators. Five extraordinary physician-scientists were given the award this year, receiving \$450,000 each over three years to pursue patient-focused research.



Joshua D. Schiffman, MD



Zsofia K. Stadler, MD



Jean Y. Tang, MD, PhD

MARIE BLEAKLEY, MD, PhD

RICHARD LUMSDEN FOUNDATION INVESTIGATOR

Bone marrow transplantation is the only effective therapy for many leukemia patients. Certain immune cells, called T cells, can cause a “graft versus leukemia” (GVL) effect that eliminates leukemic cells. Unfortunately, there are also T cells that can cause a life-threatening condition called “graft versus host disease” (GVHD). Marie focuses on developing new approaches to separate the beneficial GVL effect from detrimental GVHD after bone marrow transplantation.

Mentor: Stanley R. Riddell, MD

Fred Hutchinson Cancer Research Center, Seattle, Washington

RALPH J. DeBERARDINIS, MD, PhD

Cancer cells use specific metabolic pathways to fuel their growth into tumors. Very little is known about which pathways drive the growth of actual tumors in cancer patients. Ralph plans to use novel, highly sensitive methods to study metabolism in primary human brain tumors, and to image these activities in growing tumors. This approach should also be applicable to other cancer types and will be important for disease imaging and therapy.

Mentor: Helen H. Hobbs, MD

University of Texas Southwestern Medical Center, Dallas, Texas

JOSHUA D. SCHIFFMAN, MD

Ewing’s sarcoma is the second most common bone tumor in children and adolescents. Patients face a poor prognosis, yet the causes of the disease are not understood. Joshua, a pediatric oncologist, will study the genes of patients with Ewing’s sarcoma and their parents. He will examine inheritance and genetic

\$2.8M Invested in 18 Elite Fellows

In July, we awarded \$2.8 million in Damon Runyon Fellowship Awards to eighteen of the most creative young minds in the nation. These postdoctoral fellows are conducting promising basic research under the mentorship of distinguished cancer researchers. The three-year award provides each recipient with \$156,000, giving them the independence to explore their own innovative ideas.

PEDRO J. BATISTA, PhD

KENNETH G. AND ELAINE A. LANGONE FELLOW

with his sponsor Howard Y. Chang, MD, PhD, at Stanford University School of Medicine, investigates the molecular mechanism by which long noncoding RNAs regulate gene expression. Understanding this will allow the development of powerful tools for diagnosis and treatment of cancer.

DAVID K. BRESLOW, PhD

CONNIE AND BOB LURIE FELLOW



with his sponsor Maxence V. Nachury, PhD, at Stanford University, studies a cellular structure that

enables cells to sense and respond to specific external cues. Disruptions to this structure can promote tumor formation and cause developmental defects. He is using a combination of genetic, biochemical and imaging approaches to determine how lipid molecules contribute to these processes.

LEON Y. CHAN, PhD

HHMI FELLOW

with his sponsor Karsten Weis, PhD, at the University of California, Berkeley, focuses on how cells slow their growth rate in response to stress. He studies how stress signals relate to the cellular machinery that directs growth. Because tumor cells are constantly under stress yet grow rapidly, it is critical to understand how stress signaling and growth control are coordinated.

ADAM DE LA ZERDA, PhD

with his sponsor Carolyn R. Bertozzi, PhD, at the University of California, Berkeley, is developing imaging technology to monitor unique sugar patterns on the surface of prostate cancer cells. The patterns contain information about tumor aggression and responsiveness to therapy. This technology will help determine which patients may benefit from treatment vs. “active surveillance.”

SARAH E. EWALD, PhD

DENNIS AND MARSHA DAMMERMAN FELLOW



with her sponsor John C. Boothroyd, PhD, at Stanford University School of Medicine, studies the relationship

between a parasite and its host cell. Most cells in the body are equipped with infection sensors that can trigger cell suicide and recruit immune cells to the area. She hopes to identify novel sensors that can be used to develop targeted anti-tumor therapies.

XI HUANG, PhD

with his sponsor Lily Y. Jan, PhD, at the University of California, San Francisco, investigates how ion channel proteins promote brain tumor growth. He hypothesizes that medulloblastoma uses a specific ion channel to grow and metastasize. By exploring the role of the ion channel in medulloblastoma, he aims to find new markers for diagnosis and develop novel therapies.

CALVIN H. JAN, PhD

REBECCA RIDLEY KRY FELLOW

with his sponsor Jonathan S. Weissman, PhD, at the University of California, San Francisco, is developing new ways to examine the spatial control of gene expression within the cell. Spatially localized mRNA translation influences cell processes that are disrupted in cancer—particularly during metastasis.

HYUN YOUK, PhD

HHMI FELLOW



with his sponsor Wendell A. Lim, PhD, at the University of California, San Francisco, aims

to use quantitative models and experiments in yeast to unravel the central principles that enable cells to communicate with each other in multicellular clusters, such as tumors, and respond to external biochemical signals.

changes in order to identify novel genetic risk factors for Ewing's sarcoma, which can be used for future preventative and therapeutic strategies.

Mentor: Stephen L. Lessnick, MD, PhD
Univeristy of Utah, Salt Lake City, Utah

ZSOFIA K. STADLER, MD

Inherited genetic traits are important indicators of cancer risk but are also poorly understood. Zsofia is a clinical geneticist whose goal is to uncover the genetic basis of "sporadic" cancers, like testicular germline cancer, in young adults. She will use high-resolution sequencing technology to compare the whole genomes of patients to those of their parents, with the goal of identifying rare genetic variants associated with cancer susceptibility.

Mentor: Kenneth Offit, MD, MPH and Michael H. Wigler, PhD
Memorial Sloan-Kettering Cancer Center, New York, New York

JEAN Y. TANG, MD, PhD

Basal cell carcinoma (BCC) is the most common type of skin cancer. Mutations in the Hedgehog (HH) signaling pathway are frequently found in these cancers. Early-stage clinical studies of a HH pathway inhibitor drug have been successful, with 55% of patients reported to respond. However, most tumors change during the course of therapy and drug resistance eventually develops. Jean, a dermatologist, will work to better understand drug resistance and identify new drug combinations for use against BCC. Her studies have the potential to benefit patients with BCC and those with other HH-dependent cancers, like medulloblastoma.

Mentor: Philip A. Beachy, PhD, and Ervin H. Epstein, MD
Stanford University, Stanford, California

2011 Clinical Investigator Continuation Grants

We have awarded Continuation Grants to four Damon Runyon Clinical Investigators, providing each an additional \$300,000 to use over two years. This funding is designed to support those Clinical Investigators who need extra time and resources to complete a promising avenue of research or begin or continue a clinical trial.

ANDREW T. CHAN, MD, MPH

IMPROVING IMAGING TECHNIQUES FOR COLORECTAL CANCER
Massachusetts General Hospital, Boston, Massachusetts

RACHAEL A. CLARK, MD, PhD

CHARACTERIZING T CELLS TO DETECT MERKEL CELL CARCINOMA
Brigham and Women's Hospital, Boston, Massachusetts

VASSILIKI KARANTZA, MD, PhD

UNDERSTANDING AUTOPHAGY IN BREAST & PANCREATIC CANCERS
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey

ELAHE A. MOSTAGHEL, MD, PhD

Genentech Investigator
DEVELOPING NOVEL TREATMENTS FOR PROSTATE CANCER
Fred Hutchinson Cancer Research Center, Seattle, Washington

WAN-JIN LU, PhD MERCK FELLOW



with her sponsor Philip A. Beachy, PhD, at Stanford University School of Medicine, investigates how cells interact with their surrounding microenvironment. She aims to better understand the underlying mechanisms of regeneration and how they influence the initiation and growth of malignant tumors.

MAURIZIO RIGHINI, PhD

MERCK FELLOW
with his sponsor Carlos Bustamante, PhD, at the University of California, Berkeley, aims to characterize the dynamics of protein synthesis (translation). His research will provide insight on how it can be controlled, allowing him to build a detailed model of translation that may suggest new strategies for cancer therapy.

SUMEET SARIN, PhD

MARION ABBE FELLOW



with his sponsor Joshua R. Sanes, PhD, at Harvard University, is studying how neurons use

unique molecules on their cell surface to recognize one another during development, a critical process for spatial patterning and organ formation. A hallmark of cancerous cells is the disruption of these patterns.

DANIEL SCHMIDT, PhD

NORMAN B. LEVENTHAL FELLOW
with his sponsor Edward S. Boyden, PhD, at Massachusetts Institute of Technology, focuses on the difficult-to-treat brain cancer glioblastoma multiforme. He aims to develop bioengineered molecules to investigate the role of ion channel proteins in glioblastoma growth and metastasis.

YOKO SHIBATA, PhD

HHMI FELLOW
with her sponsor Richard I. Morimoto, PhD, at Northwestern University, focuses on specialized protein quality control (QC) mechanisms, which ensure the proper folding of new proteins and disposal of mature ones and play a pivotal role in protecting the genome. She aims to identify the components that make up the nuclear protein QC system, which may serve as new therapeutic targets.

DENIZ SIMSEK, PhD

PHILIP O'BRYAN MONTGOMERY, JR., MD FELLOW



with her sponsor David P. Toczyski, PhD, at the University of California, San Francisco, studies the role of ubiquitin protein signals in maintaining genome integrity in yeast. Components of this system are highly conserved from yeast to

humans, so insights gained from its study may identify additional targets to combat cancer.

COLE TRAPNELL, PhD

with his sponsor John L. Rinn, PhD, at Harvard University, studies the role of long noncoding RNAs (lncRNAs) in cancer. When tissue is damaged, this class of genes may cause cancer or make it difficult to treat. Using sequencing software and mathematics that he developed, he aims to discover which genes are misregulated by lncRNA in tumor cells.

SCOTT J. VALASTYAN, PhD

with his sponsor Joan S. Brugge, PhD, at Harvard Medical School, seeks to uncover regulators of breast cancer metastasis. He has devised a novel experimental system that is capable of defining and exploiting the phenotypic heterogeneity and genetic diversity that exists within tumor cell populations.

ALEXANDER WARD, PhD

HHMI FELLOW
with his sponsor Liqun Luo, PhD, at Stanford University, is studying key genetic pathways that may play a role in development of neurons in the *Drosophila* olfactory system. Many of the genes in these pathways are also involved in cancer. The ultimate goal of this research is to identify the upstream cell surface effectors of these pathways, thus providing further insight into cancer signaling.

HUA LU, PhD

THE JAKE WETCHLER FOUNDATION FELLOW FOR PEDIATRIC INNOVATION
with his sponsor Peter G. Schultz, PhD, at The Scripps Research Institute, aims to develop antibody-drug conjugates (ADCs) that can recognize and kill AML cells. His goal is to generate specific ADCs that will attack tumor cells without harming normal cells.

INNOVATIVE RESEARCH FOR PEDIATRIC CANCER

The Jake Wetchler Foundation for Innovative Pediatric Cancer Research has made its first grant, sponsoring Damon Runyon Fellow Hua Lu, PhD, at the Scripps Institute in La Jolla, California. The Foundation was started by Jean Singer and John Wetchler in honor of their son Jake, who beat Hodgkin's lymphoma at age 18 before losing his life to leukemia at 20. "With this project, we've landed a solid first punch in the fight against pediatric cancer, for Jake and all the kids who today need better treatments and cures," they said.

ALUMNI PROFILE: LINDA S. BIRNBAUM, PhD



Linda S. Birnbaum, PhD

The identification of carcinogens—cancer-causing substances—is critical to preventing cancer. Leading this important effort is Linda S. Birnbaum, PhD, a former Damon Runyon Fellow and the first woman to serve as director of the National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program.

The NIEHS is a federal agency charged with understanding how human environments influence disease. “You can’t change your genes,” Linda says, “but you can change your environment.” A 2010 inductee into the prestigious Institute of Medicine and a federal scientist for more than 30 years, she is a renowned expert in understanding how exposure to persistent chemicals in the environment contributes to diseases like cancer.

Her fascination with environmental health sprung from her early research on how metabolic changes in chemicals impact aging. After witnessing the effects of chemicals like dioxin and PCBs on rat models, she began studying how they break down in the human body and designing experiments to assess cancer risk. “If anybody had told me that 30 years later I’d still be working with that same family of chemicals, I wouldn’t have believed them,” she said.

Today, she oversees the publication of the influential Report on Carcinogens, which in 2011 added chemical formaldehyde and aristolochic acids to the list of known human carcinogens. Dioxin was added in 1981, and PCBs were listed as “reasonably anticipated to be a human carcinogen” the same year. There are now 54 known and 186 “reasonably anticipated” carcinogens in the report.

As the first toxicologist to lead the NIEHS, Linda is leveraging her research prowess for the public good. “The most important thing you should learn as a scientist is how to ask the right questions,” she told LASNews Magazine. She’s doing just that by re-thinking the agency’s approach and expanding collaboration across fields. “We’re addressing it at this point...on a one-chemical-at-a-time basis. We need...strategies to look more broadly, because no one’s exposed to one chemical at a time,” she explained.

WAYS TO GIVE

PLAN TO FUND FUTURE BREAKTHROUGHS

When you remember the Foundation in your will or estate, you are funding future cancer breakthroughs. Many planned giving strategies exist that may provide you with significant tax savings. For advice, please contact us.

SPONSOR A SCIENTIST

Sponsor a Damon Runyon scientist and play an active role in the development of future cancer treatments and cures. We will name the award for you, your family, or in honor of someone you choose.

ANNUAL AND MONTHLY GIVING

Annual or monthly gifts are easily made and very much appreciated. You can donate by mail, by phone or via our secure website at www.damonrunyon.org.

TRIBUTES

Make a donation in memory, in honor, or for birthdays and celebrations. A tasteful card will be sent on your behalf.

BROADWAY TICKETS

Enjoy access to top ‘house’ seats at Broadway shows and support cancer research. Gift certificates are available and we welcome corporate clients. Call 212.455.0550 or visit www.damonrunyon.org/broadway.

DONATE ONLINE

You can easily donate online via our secure website at www.damonrunyon.org

To learn more about ways to support the Damon Runyon Cancer Research Foundation, contact us at 212.455.0500 or visit www.damonrunyon.org/donate

ABOUT US

To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research.

Damon Runyon scientists, including 11 Nobel Laureates, have made some of the most important discoveries in cancer research, including:

1954

Confirming the link between cigarette smoking and lung cancer

1970

Identifying the first cancer-causing gene

2008

Arming the immune system to fight melanoma

IN 65 YEARS, THE FOUNDATION HAS INVESTED MORE THAN **\$240 MILLION** AND FUNDED MORE THAN **3,330 SCIENTISTS**.



Walter Winchell



Damon Runyon

OUR HISTORY

The Foundation was created in 1946 following the death from cancer of Damon Runyon, the writer whose beloved Broadway stories inspired the musical *Gypsy* and *Dolls*. Walter Winchell, a famous journalist and radio star, founded the fund and led it with the help of celebrities including Marlene Dietrich, Bob Hope, Marilyn Monroe and Joe DiMaggio.

DISCOVERING THE TALENT TO DISCOVER THE CURE

100%

OF ALL DONATIONS SUPPORT CUTTING-EDGE CANCER RESEARCH

Our low administrative and fundraising costs are paid by Damon Runyon Broadway Tickets and our endowment.

Accelerating Cancer Cures Runyon 5K Raises \$650,000
Honoring a Boston Leader Emerging Leaders in Clinical Research
\$2.8M Invested in 18 Elite Fellows Alumni Profile: Linda S. Birnbaum, PhD



Have a Seat, Help a Scientist

Damon Runyon Broadway Tickets offers you the best seat locations for dozens of Broadway shows and supports cancer research. We rely on word of mouth, so please tell your friends about our service or introduce them with our Broadway gift certificates. They can even choose the shows and performances themselves!

Our decades-long relationship with Broadway theaters plays a major role in supporting our brilliant young scientists. Tickets are competitively priced, and half of the cost is a tax-deductible contribution to cancer research.

To reserve tickets or buy a gift certificate, call 212.455.0550 on weekdays between 9 a.m. and 5 p.m. or visit www.damonrunyon.org/broadway for more information.

2011 FALL SEASON SHOWS

OCTOBER

Chinglish

The hilarious story of an American businessman desperate to launch a new enterprise in China.

The Mountaintop

A new play reimagines the events of the night before Dr. Martin Luther King, Jr.'s assassination in 1968. Starring Samuel L. Jackson and Angela Bassett.

Relatively Speaking

John Turturro's directorial Broadway debut with a trio of one-act comedies written by Ethan Coen, Elaine May, and Woody Allen.

NOVEMBER

Other Desert Cities

The Off-Broadway hit drama about a promising writer returning to her estranged parents to announce she is about to publish a memoir exposing painful family secrets.

Starring Stockard Channing, Rachel Griffiths, Stacy Keach and Judith Light.

Godspell

The revival of the beloved classic from Stephen Schwartz. Starring Hunter Parrish.

Private Lives

The comedy revival about a divorced couple who realize they can't quite give each other up while honeymooning with their new spouses. Starring Kim Cattrall and Paul Gross.



Seminar

A dark comedy about four young writers thrilled to be participating in a private seminar taught by the brilliant but unpredictable Leonard, an international literary legend. Starring Alan Rickman.

An Evening with Patti LuPone and Mandy Patinkin

The two legendary theatre artists join together to perform a masterful selection of some of the greatest songs written for the stage.

DECEMBER

Bonnie and Clyde


With a mix of rock and blues, the new musical examines how a troubled Texas teen and a love-sick waitress became America's most infamous couple.

Stick Fly

A comedy that follows two brothers from an affluent African American family who come together with their fiancées to spend a weekend at their stately Martha's Vineyard mansion.

On a Clear Day You Can See Forever

The musical revival that tells the story of a psychiatrist who falls in love with his patient after putting her under hypnosis. Starring Harry Connick, Jr.



Lysistrata Jones

A new musical that tells the story of a hapless basketball team and its cheerleaders, who won't "give it up" until the team wins a game.

POPULAR AND ACCLAIMED

The Book of Mormon

The Tony Award-winning musical from the creators of South Park and Avenue

Q that follows two young Mormons on a mission to spread the gospel in dangerous parts of Uganda.



War Horse

Nick Stafford's adaptation of the beloved book uses puppetry to bring the story of a young man named Albert and his beloved horse, Joey, to life.

Damon Runyon Cancer Research Foundation

BOARD OF DIRECTORS

Chairman

Alan M. Leventhal

Vice Chairmen

Leon G. Cooperman
David M. Livingston, MD
Sanford W. Morhouse, Esq.
Mr. David M. Beirne
Michael L. Gordon

Steven J. Burakoff, MD
William L. Carroll, MD
Gary E. Erlbaum
Thomas J. Fahey, Jr., MD
Buck French
Dale F. Frey
John A. Fry
Elaine V. Fuchs, PhD
Richard B. Gaynor, MD
Margaret A. Gilliam
Todd R. Golub, MD
Scott Greenstein
Steve Hayden
Bill Helman
Jay W. Ireland
Steven A. Kandarian
Noah Knauft
Ronald Levy, MD
David G. Marshall
John H. Myers
Richard J. O'Reilly, MD
Katharine F. Plum
Andrew S. Rachleff
Scott Ryles
Karen D. Seitz
William R. Sellers, MD
Samuel C. Silverstein, MD

One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006

Administration
212.455.0500
Fax 212.455.0509

Broadway Ticket Sales
212.455.0550

To receive our newsletter via e-mail, please contact us at 1.877.7CANCER or info@damonrunyon.org or www.damonrunyon.org



PREMIER CIRCLE

WHEN YOU JOIN the Damon Runyon Premier Circle, you receive special early access to our limited-supply, premium house seats. You will get two complimentary tickets to a show of your choice, special invites to our theatre benefits for reduced prices and recognition in our Annual Report. Most importantly, you are investing in new cures. **To learn more, call 212.455.0550 or email tickets@damonrunyon.org.**